Blog
Log In
Contact us

Category: News

Categories
Featured News

OMNY Health Wins Fierce Healthcare Innovation Award for Clinical Information Management 

We are thrilled to announce that OMNY Health has been named a winner in the prestigious Fierce Healthcare Innovation Awards for our groundbreaking work in Clinical Information Management! 

This recognition from Fierce Healthcare, a leading voice at the intersection of healthcare, business, and policy, celebrates the organizations that are driving improvements and truly transforming the industry. 

OMNY Health was honored specifically for our innovative work on Unstructured Clinical Notes, demonstrating our unwavering commitment to unlocking the full potential of real-world data to advance research, power AI, and ultimately, improve patient care. 

OMNY’s Eric Lavin, SVP Commercial, and Dr. Mitesh Rao, CEO at the Fierce Innovation Awards in New York City

Unlocking the Hidden Context of Care 

The majority of critical patient context is often buried within unstructured data inside the Electronic Health Record (EHR). This context includes the nuances of a diagnosis, the challenges of a treatment plan, and the social factors affecting a patient’s journey, such as physician notes, discharge summaries, and clinical reports. This information is notoriously difficult to access, integrate, and utilize at scale. 

Our ground-breaking solution tackles this challenge head-on. OMNY Health’s platform transforms billions of these complex, siloed, unstructured clinical notes into high-quality, regulatory-grade, and AI-ready datasets. By linking this deep, contextual information with structured clinical data, we provide a holistic, longitudinal view of the patient experience. 

This capability is essential for: 

  • Fueling Responsible AI: Providing clean, unbiased, and comprehensive datasets to train next-generation clinical and operational AI models. 
  • Accelerating Research: Giving life sciences and healthcare researchers the necessary context to understand treatment efficacy, patient subpopulations, and complex disease progression. 
  • Driving Health Equity: Ensuring that data used for research and development is truly representative of the national population, including diverse geographies, ethnicities, and care settings. 

A Mission Confirmed 

This award is a powerful validation of our democratic approach to healthcare data, which focuses on partnering directly with provider organizations to create a nationally representative “living data layer.” 

“To be recognized by Fierce Healthcare for our work in Clinical Information Management is a tremendous honor and underscores the criticality of solving the unstructured data problem,” said Mitesh Rao, M.D., CEO and co-founder of OMNY Health. “The true voice of the patient and the context of their care often reside in those notes. By making this data accessible and usable, we are giving researchers, developers, and health systems the fuel they need to deliver on the promise of precision medicine and responsible AI.” 

The Future of Real-World Data 

At OMNY Health, we believe that clean, usable, and representative data is the foundation of a better healthcare future. We are proud to stand among the industry’s most innovative companies and remain committed to expanding our platform to help our partners accelerate discovery and improve outcomes for millions of patients across the nation. 

 

Learn more about the awards and our category win on the official Fierce Healthcare Innovation Awards page. 

Discover how OMNY Health is transforming real-world data for your organization at omnyhealth.com. 

Categories
News

OMNY Health Chosen to Present at Venture Atlanta 2025, the Southeast’s Premier Tech Conference

Now in its 18th year, Venture Atlanta has helped launch 930 companies, raise more than $8 billion in funding, and achieve $20.8 billion in successful exits to date 

 ATLANTA – September 11th, 2025 – OMNY Health is proud to announce its selection as one of the Southeast’s most promising tech companies to present at Venture Atlanta 2025. The event, to be held October 15-16 at The Woodruff Arts Center and Atlanta Symphony Hall, brings together visionary startups and growth-stage companies with hundreds of the nation’s top-tier investors. As the Southeast’s premier platform for tech innovation, growth, and capital access, Venture Atlanta continues to be a launchpad for companies shaping the future. 

Now in its 18th year, Venture Atlanta has helped launch over 930 companies, facilitating over $8 billion in funding and $20.8 billion in successful exits to date. This year, the event has expanded to include new founder pathways, curated networking, and procurement programming to attract over 1,600 attendees, including 450 investment funds from across the U.S. 

“We are incredibly honored to be selected to present at Venture Atlanta 2025. This city has become a hub for health tech innovation, and Venture Atlanta is the premier platform where the future of the industry gets shaped. To be recognized among a peer group of such promising, high-growth companies is a testament to our team and the critical infrastructure we are building. We look forward to sharing how OMNY’s healthcare data ecosystem will fuel the next generation of life-changing innovation.” 

As in previous years, Venture Atlanta 2025 is anticipated to be a sold-out event. 

“Venture Atlanta is where companies come to get discovered,” said Venture Atlanta CEO Allyson Eman. “To be selected in a year as competitive as this one speaks volumes about the strength and potential of these startups. These companies didn’t just stand out—they’re poised to break out. With hundreds of investors in the room and a highly curated audience, the visibility companies get here often leads directly to the funding, partnerships, and momentum they need to thrive. We’re incredibly proud to help founders gain the exposure and support that accelerates their path to success.” 

This year’s Venture Atlanta will once again bring together the Southeast’s most promising technology companies and the investors eager to discover them. With applications from across the region—including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, North Carolina, South Carolina, Mississippi, Tennessee, Texas, Virginia, and Washington, D.C.—the 2025 conference offers a rare opportunity to see the region’s top innovators all in one place. 

Venture Atlanta boasts a roster of highly successful alumni, including Bark, CallRail, Car360, Flock Safety, Florence Healthcare, ParkMobile, Salesloft, Kabbage, Bitcoin Depot, PrizePicks, Stax, SingleOps, Pindrop, Terminus, and many others. 

To learn more about OMNY Health, visit www.omnyhealth.com.  For additional information about Venture Atlanta, to register for the event, or to view the conference schedule, please visit www.ventureatlanta.org.  

 

About Venture Atlanta 

Venture Atlanta, the Southeast’s technology innovation event, is where the region’s most promising tech companies meet the country’s top-tier investors. As the Southeast’s largest investor showcase helping launch 930 companies and raise over $8 billion in funding to date, the event connects the region’s top entrepreneurs with local and national investors and others in the technology ecosystem who can help them raise the capital they need to grow their businesses. The annual nonprofit event is a collaboration of the Atlanta CEO Council, Metro Atlanta Chamber, and the Technology Association of Georgia (TAG). For more information, visit www.ventureatlanta.org. For updates, follow us on Twitter and LinkedIn, and visit our blog. 

 

About OMNY Health 

OMNY Health™ is the leading healthcare ecosystem for compliant real-world data insights at scale. OMNY Health connects patients, providers, and life sciences companies by transforming vast amounts of de-identified electronic health record data, clinical notes, and claims data into robust, research-ready insights. Leveraging proprietary AI, NLP, and LLM technologies, OMNY Health accelerates therapeutic innovation, optimizes clinical development, and enhances patient care. For more information, visit www.omnyhealth.com. 

Categories
News

OMNY Health Dataset Hits 100 Million Patient Milestone, Unlocking Unprecedented Access to Healthcare Data for Research

Spanning nearly 30 percent of the U.S. population, the de-identified data available includes insights from unstructured clinical notes, electronic medical records, and medical claims

ATLANTA, GA – July 31, 2025 – OMNY Health, the leading healthcare ecosystem for compliant real-world data (RWD) insights at scale, today announced its data network now officially encompasses insights from more than 100 million patients across all 50 U.S. states. This landmark achievement solidifies OMNY Health’s position as a premier source for comprehensive, HIPAA-compliant de-identified RWD, providing life sciences organizations, healthcare providers, and AI innovators with unparalleled access to standardized, rich, longitudinal patient journeys.

Since onboarding its first provider partner in 2020, OMNY Health has expanded to include more than 46 leading healthcare organizations, including St. Luke’s University Health Network, Bon Secours Mercy Health, and Baptist Health System KY & IN, providing a comprehensive view of patient care. The data on its platform spans more than eight years of historical data, including billions of clinical encounters from more than 650,000 providers as well as 6.5 billion clinical notes, making it the deepest repository of unstructured clinical knowledge in the country. The breadth of the OMNY health platform enables deeper insights into disease progression, treatment patterns, and patient outcomes. Additionally, OMNY Health’s data spans every therapeutic area, with most having comprehensive data from more than 10 million patients each, further supporting its diverse use cases across the healthcare ecosystem.

“Unlocking AI’s transformative power in healthcare demands a new approach for collaboration. It’s not just about volume of data, but more importantly, about the quality, diversity, and real-world representation of the data available to researchers,” said Matthew Fenty, Managing Director for Innovation & Strategic Partnerships at St. Luke’s University Health Network. “From their beginnings, OMNY Health has maintained a keen understanding of this critical need and provides a platform that empowers health systems like ours to securely contribute and collectively build the rich, diverse data foundation essential for cutting-edge AI development. Our participation with OMNY Health is a testament to our commitment to advancing patient care through responsible data innovation.”

“The healthcare industry has witnessed time and again how the power of collective knowledge and collaboration can improve the outlook on complex healthcare challenges. The COVID-19 pandemic was a stark reminder of the need for sharing de-identified data to close information gaps,” said Mark Townsend, MD, MHCM, Chief Clinical Digital Ventures Officer, Bon Secours Mercy Health and Accrete Health Partners. “We are proud to partner with OMNY as they continue to bring stakeholders together, ensuring that shared data drives innovation safely and responsibly.”

Brett A. Oliver, MD, Chief Medical Information Officer at Baptist Health System KY & IN, added, “Artificial intelligence is only as smart as the patchwork quilt of information we feed it. At Baptist Health, we’ve learned that real clinical insight—and true equity—emerges only when every thread of the patient story is woven into the model. That’s why OMNY Health’s drive to knit together a living, breathing data network isn’t just helpful; it’s the loom on which tomorrow’s breakthroughs will be spun. We’re thrilled to keep adding squares to that ever‑growing quilt.”

OMNY Health’s proprietary AI, Natural Language Processing (NLP), and Large Language Model (LLM) technologies are central to this achievement, transforming vast amounts of raw, often unstructured, clinical information found in clinical notes into research-ready variables. This unique capability allows researchers to uncover nuances buried in free-text clinician notes – details on symptoms, adverse events, treatment rationales, and social determinants of health – that are critical for a complete understanding of real-world patient experiences.

“Reaching 100 million patient lives is a monumental step forward in our mission to accelerate life-changing innovations through data-driven insights,” said Dr. Mitesh Rao, Founder and CEO of OMNY Health. “This milestone could not have been achieved without the ongoing support of our data partners. We’re incredibly grateful to collaborate with leading organizations that share our vision for advancing healthcare research. As we continue to grow, we look forward to expanding the platform to impact more lives and solve some of the most difficult problems in healthcare.”

OMNY Health plans to continue to expand its dynamic network of specialty health networks, hospitals, academic medical centers, and integrated delivery networks across the U.S., with the goal of achieving more than 125 million patient lives on the platform by the end of 2025. For more information on OMNY Health and its data platform, please visit www.omnyhealth.com.

###

About OMNY Health OMNY Health™ is the leading healthcare ecosystem for compliant real-world data insights at scale. OMNY Health connects patients, providers, and life sciences companies by transforming vast amounts of de-identified electronic health record data, clinical notes, and claims data into robust, research-ready insights. Leveraging proprietary AI, NLP, and LLM technologies, OMNY Health accelerates therapeutic innovation, optimizes clinical development, and enhances patient care. For more information, visit www.omnyhealth.com.

Categories
News

OMNY Health Adds More Than 300 Health Measures to Enhance Disease Progression Research and Treatment Monitoring

The Company Now Offers Insights Across Ten Specialty Areas, Including Dermatology, Respiratory, Cardiovascular, Autoimmune, Gastroenterology, and Neurology

ATLANTA – May 8, 2025 – OMNY Health, the leading healthcare ecosystem for compliant real-world data insights at scale, today announced it has expanded its data network by adding more than 300 clinical assessment measures. These disease-specific measures include information derived from clinical severity indicators, surveys, and questionnaires, such as the Crohn’s Disease Activity Index (CDAI) and the Harvey Bradshaw index for Gastroenterology, as well as the Asthma Control Test and COPD Assessment Test (CAT) for Respiratory. These measures provide a more granular, real-world view of patient health, enhancing the ability to monitor disease progression and treatment impact.

The new measures incorporate data extracted and curated from structured and unstructured sources within OMNY Health’s extensive data pool of electronic health records (EHRs) to enhance the research and insights into medical specialties such as respiratory, cardiovascular, autoimmune, gastroenterology, neurology, and oncology. Adding these new pan-therapeutic measures builds on OMNY Health’s successful data strategy in dermatology, where it first demonstrated the value of leveraging disease-specific measures.

“For some time, OMNY Health has been seen as a dermatology data network, but with our network growth, we are moving beyond that and demonstrating the value of our solutions to the broader healthcare community,” said Dr. Mitesh Rao, CEO and Co-Founder of OMNY Health. “By leveling up research and making more information available across multiple specialties, OMNY Health enables teams to fill information gaps, accelerate research timelines, and make meaningful improvements to patient care.”

OMNY Health’s curated measures offering includes data on:

  • Longitudinal disease progression, flare-ups, and treatment responses for conditions such as asthma, COPD, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, lupus, epilepsy, and multiple sclerosis
  • Real-world evidence on risk factors, medication adherence, and patient outcomes for conditions like heart failure and hypertension
  • Post-surgical recovery tracking, rehabilitation outcomes, and treatment effectiveness for various conditions

By capturing a broader range of clinical information across a larger and diverse set of provider organizations, OMNY Health’s measures provide deeper and more representative insights than traditional disease-specific registries, positioning the company as a go-to source for researchers seeking information and data.

“Democratizing access to longitudinal data that has both breadth and depth has been a longstanding challenge for healthcare researchers like myself,” said Dr. T. Y. Alvin Liu, Inaugural Director of the James P. Gills Jr. MD and Heather Gills Artificial Intelligence Innovation Center at Johns Hopkins Medicine. “As AI begins to leave its mark on the healthcare industry, these new measures from OMNY come at a pivotal time, guaranteeing the highest quality of data to researchers and actionable information to healthcare executives. By taking previously untapped data sources and turning them into resources for better care, we can provide more precise and accurate treatments to patients across care specialties and unparalleled insights for executives to make decisions on a system level.”

OMNY Health’s release of more than 300 new health measures to its data ecosystem follows the company’s announcement in March of the availability of  4 billion unstructured clinical notes. This enabled the company to support its customers in unlocking previously hidden insights, which will drive a better understanding of patient journeys and unleash new innovations in treatment options. For more information on OMNY Health and its data ecosystem, please visit www.omnyhealth.com.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, hospitals, academic medical centers, and integrated delivery networks span all fifty states and cover over 85 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data network now reflects more than eight years of historical data encompassing more than 4 billion clinical notes from 1 billion encounters, 500,000+ providers across 200+ specialties – and is growing. To learn more about how OMNY Health transforms lives and drives patient care by connecting providers and life sciences companies through data, visit www.omnyhealth.com.

Media Contact

SolComms

Caroline Rueve

OMNY@solcomms.co

847-609-4055

Categories
News

OMNY Health Becomes the First EHR Dataset Available on Datavant Connect Powered by AWS Clean Rooms

OMNY Health, the leading healthcare ecosystem for compliant real-world data insights at scale, today announced it has become the first electronic health record (EHR) company to offer its real world data (RWD) dataset on Datavant Connect powered by AWS Clean Rooms through its Lighthouse Partner Program.

Categories
News

GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds

Categories
News

OMNY Health and Scipher Medicine Partner to Revolutionize Autoimmune Disease Treatment with Clinico-Transcriptomics Data

Categories
News

OMNY Health Launches Dynamic GLP-1 Network of 600,000+ Patients to Fuel Clinical Research on Its Use

New Studies on the Use of These Medications in Adult and Pediatric Populations are Supported by the Data Network

Atlanta, Georgia – August 27, 2024 – OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data partnerships, today announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, further cementing the company’s commitment to democratizing healthcare data across industries. This new data network comprised already of over half a million patients will supply its life sciences and health system partners, as well as its AI-driven health tech partners, with additional knowledge of GLP-1 use, related social determinants of health (SDOH), and patient demographics to better inform generative AI tools, researchers, and clinicians and improve patient outcomes.

Despite a staggering amount of healthcare data being generated across health systems and life sciences companies, 97% of this data goes unused. This underutilization is particularly crucial as the usage of GLP-1 agonists surge, driven by their effectiveness in treating chronic conditions such as type 2 diabetes and obesity. The growing demand for these medications has sparked an urgent need for more comprehensive data that evaluates their effectiveness and long-term effects for other conditions like cardiovascular disease, liver disease, and skin disorders.

“GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways. The systemic impact of these medications underlines the need for more comprehensive data to fully understand how these therapies affect patients as a whole,” said Dr. Mitesh Rao, CEO of OMNY Health. “By democratizing data partnerships between life sciences companies and health systems, we can enable more in-depth clinical research that will fuel healthcare innovation and revolutionize the potential impact of GLP-1’s for years to come.”

OMNY’s GLP-1 data network consists of curated EMR data from more than 645,000 patients representing a broad set of demographic characteristics, including age ranges, race/ethnicity, region of care delivery, as well as provider and payer types. The data network supported two recent studies that address gaps in understanding GLP-1 therapies, particularly within pediatric and patient populations impacted by SDOH factors enabling partner companies to better understand and apply findings to patient treatments.

Pediatric use of GLP-1s was not approved by the FDA until December 2022, making data on these use-cases extremely limited despite the prescriptions of GLP-1RAs for children and adolescents increasing by 594.4% from 2020 to 2023. OMNY’s GLP-1 network contains valuable information on pediatric GLP-1 use, enabling a study that found the median age of users was 16 years and the majority were female in gender (72%).

“We are able to deliver more equitable clinical outcomes when the research is backed by data from diverse populations,” said Dr. Sameer Badlani, Fairview Health Services’ Executive Vice President, and Chief Strategy Officer. “With access to data that factors in SDOH for diverse populations we learn valuable insights in service of providing resources and clinical care that is differentiated by excellence in quality, safety, experience and health equity for every consumer who trusts us with their wellness and care.”

OMNY’s network also provides critical information on SDOH factors, including economic insecurity, food insecurity, and social isolation often documented in clinician notes. With many of these factors accounting for up to 50% of the variation in health outcomes in the US, it was crucial that the SDOH status of patients receiving GLP-1 treatment be made available. A second study by OMNY found that GLP-1 patients were half as likely to have SDOH economic burden issues noted in their EHR record as compared the population of non-users.

OMNY’s data network enables companies to diversify their patient populations for clinical trials, better understand medication interactions, and strengthen treatment outcomes.

This announcement follows OMNY’s partnerships with QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and the creator of LifeSphere®. OMNY Health is committed to AI-enabled healthcare improvement and supporting research programs that aim to improve clinical care. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit www.marketing-dev.omnyhealth.com.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties – and is growing. For more information, visit www.marketing-dev.omnyhealth.com.

Media Contact:

Chloe Fredericksdorf
omnyhealth@solcomms.co.

Categories
News

OMNY Health Launches Data Platform Designed to Power AI-Driven Health Tech Companies

OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data sharing launched its platform designed to power AI-driven health technology companies, further cementing the company’s commitment to democratizing healthcare data. QuantHealth and ArisGlobal are just two of OMNY’s newest partners to leverage this new platform to power their organizational AI-driven needs. OMNY Health’s data network uniquely addresses Generative AI’s need for large de-identified structured and unstructured electronic health record (EHR) data sets across diverse provider and patient populations, further underscoring the platform as delivering the data infrastructure and rails for provider organizations to collaborate and fuel the development and use of effective AI solutions for advancing healthcare.

“Our mission is to free data from silos, allowing it to be shared, analyzed, and morphed into life-saving treatments and better care for patients,” said Mitesh Rao, CEO, OMNY Health. “Life science organizations and providers often struggle with time and budget constraints that hinder their ability to learn from their data. Our work powering AI-driven platforms can unblock this process by partnering with AI developers with data and tools to accelerate breakthrough therapies and monitor new therapies for safety signals to ensure patient populations remain safe.”

Two of OMNY Health’s AI-driven partners being effectively powered by the platform’s data to foster new opportunities for advancing healthcare include QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®.

QuantHealth’s AI technology, trained on a dataset of 350 million patients, enhances clinical trial timelines, mitigates trial risks, and identifies populations likely to respond to treatments. OMNY’s collaboration will help QuantHealth’s pharmaceutical partners expedite drug development through simulated clinical trials, utilizing real-world evidence to predict clinical trial outcomes, drug efficacy, and patient responses.

“Biotech is entering a vibrant part of life sciences history,” said Omri Matalon, VP Clinical Data Science and Head of R&D Operations at QuantHealth. “This partnership furthers our commitment to quality data and access for our life sciences partners. By integrating diverse EHRs into organized, de-identified research data products, we can address disparities in clinical trials and close significant demographic information gaps in drug discovery and development.”

OMNY’s partnership with ArisGlobal, a leader in pharmacovigilance, safety monitoring, and reporting systems, will transform safety signal validation and pave the way for comprehensive, proactive signal detection.

“Up to 95% of adverse event cases go unreported today, while processing ICSRs can be time consuming, and analysis of medical literature and online forums is slow and inefficient,” said Ann-Marie Orange, CIO and Global Head of R&D at ArisGlobal. “Combining LifeSphere products with comprehensive real-time RWD addresses these challenges head-on. By leveraging advanced technology and insights from extensive RWD, we are reshaping drug discovery and development.”

These partnerships demonstrate OMNY Health’s commitment to AI-enabled healthcare improvement through acceleration of diverse participation in clinical trials and the support of research programs that aim to save lives and improve patient outcomes. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit https://marketing-dev.omnyhealth.com/.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties – and is growing. For more information, visit www.marketing-dev.omnyhealth.com.

About ArisGlobal

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn or visit https://www.arisglobal.com/.

About QuantHealth

90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth’s Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly. Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth’s simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai/.

Categories
News Product

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

new GI real-world data solutions

OMNY Health’s GI partnerships are a pivotal step in its mission to deliver data and insights to accelerate life-changing innovation. With a focus on catalyzing research and improving outcomes, OMNY aims to make a tangible difference for the millions of individuals in the US impacted by gastroenterology diseases

ATLANTA, GA, April 22, 2024 – OMNY Health is pleased to announce its partnership with the nation’s leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY’s research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY’s real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with the health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY’s solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

“United Digestive remains committed to offering our patients the most suitable and cost- effective healthcare solutions. Our dedication to delivering best-in-class GI care is intricately linked with our data-driven approach,” says United Digestive’s Chief Medical Officer, Dr. John Suh. “We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care.”

“As Florida’s leading gastroenterology provider, Borland Groover’s mission is to provide exceptional care and improve the lives of our patients. Achieving this objective requires a deep understanding of our patients, patterns of care, outcomes, and opportunities for further improvement through data analysis,” said Borland Groover’s CEO, Dr. Kyle Etzkorn. “Our collaboration with OMNY not only aligns with our mission, but it also presents avenues to identify and pursue future opportunities for elevating GI patient care.”

“Enhancing patient care isn’t just a goal; it’s our responsibility, guided by the personal experiences of every patient we serve. Each piece of patient data is not just a statistic; it is a pathway to better outcomes, a testament to our commitment, and a source of inspiration for ongoing progress” said Christa Newton, MBA, CEO, OneGI. “We are excited to partner with OMNY as a tangible step in realizing these guiding principles for the benefit of our patients.”

“It is important to One GI that our patients are represented when it comes to emerging research, care improvement initiatives, and best in class care. Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy to access exceptional GI care.” – Dr. Michael Dragutsky, Founder, Chairman, OneGI. Key populations available in the GI specialty offerings are aligned with the significant research and development efforts underway in gastroenterology, including ulcerative colitis, Crohn’s disease, celiac disease, short bowel syndrome, reflux disorders, and many others. Like other OMNY Health specialty-focused solutions, the GI offering includes information covering pharmacy orders, lab and diagnostic test results, comorbidities, symptom checklists, and provider clinical assessment scores. “We are thrilled to welcome our new gastroenterology providers to our network. Over the past two years, we have made great strides connecting researchers and providers participating in our dermatology and ophthalmology research networks. We look forward to building on that impact in the field of gastroenterology,” said Mitesh Rao, MD, CEO, OMNY Health.

About OMNY Health

OMNY Health connects the healthcare ecosystem through data and insights to transform healthcare delivery, improve clinical outcomes, and address patients’ unmet needs.   The OMNY platform serves as a centralized resource for healthcare stakeholders to participate in data sharing and research services at scale, fueling innovation where patients need it the most. For more information, go to https://marketing-dev.omnyhealth.com/

MEDIA INQUIRIES: media@omnyhealth.com